1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About Edwards Lifesciences Corp

Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. Edwards Lifesciences is driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape.
Michael Mussallem

1 Edwards Way
Irvine, California 92614-5688
Phone: 19492502500


Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference | EW Stock News
Feb 23, 2024 12:05pm

Edwards Lifesciences Corporation (NYSE: EW) will participate in the TD Cowen Healthcare Conference on March 5, 2024. CEO Bernard Zovighian and CFO Scott Ullem will present at 10:30 a.m. ET. A live webcast will be available on the investor relations website.

Source:Stock Titan
Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference
Feb 23, 2024 12:05pm

Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, are scheduled to present at 10:30 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, Jetzt den vollständigen Artikel lesen

Strategic Sale: Catherine Szyman Decides To Exercise Options Worth $2.32M At Edwards Lifesciences
Feb 16, 2024 15:01pm

A significant insider transaction involving the exercise of company stock options was reported on February 15, by Catherine Szyman , CVP at Edwards Lifesciences (NYSE: EW ), as per the latest SEC filing. What Happened: Szyman, CVP at Edwards Lifesciences, exercised stock options for 47,000 shares of EW stock. This information was disclosed in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday. The exercise price of the options was $36.75 per share. The Friday morning update indicates Edwards Lifesciences shares down by 0.0%, currently priced at $86.04. At this value, Szyman''s 47,000 shares are worth $2,316,630. Discovering Edwards Lifesciences: A Closer Look Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters, and monitoring systems used to measure a patient''s heart function during surgery.

Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)
Feb 14, 2024 18:27pm

No summary available.

Source:Seeking Alpha
Bad News for Edwards Lifesciences Corp. Stock: This New Risk Has Been Added
Feb 14, 2024 06:01am

Edwards Lifesciences Corp. (EW) has disclosed a new risk, in the Natural and Human Disruptions category. Edwards Lifesciences Corp. faces significa…

Q4 —…—‘ Edwards Lifesciences Corp Earnings Call Transcript
Feb 10, 2024 10:56am

Q4 2023 Edwards Lifesciences Corp Earnings Call Transcript

Q1 2024 EPS Estimates for Edwards Lifesciences Co. (NYSE:EW) Lowered by Analyst
Feb 10, 2024 07:50am

Edwards Lifesciences Co. (NYSE:EW – Free Report) – William Blair cut their Q1 2024 earnings per share (EPS) estimates for shares of Edwards Lifesciences in a report issued on Wednesday, February 7th. William Blair analyst M. Kaczor now expects that the medical research company will post earnings of $0.64 per share for the quarter, down […]

Source:The AM Reporter
Edwards Lifesciences Corp Director Heisz Stone Sells 7,…56 Shares
Feb 09, 2024 07:21am

Edwards Lifesciences Corp Director Heisz Stone Sells 7,056 Shares

These Analysts Boost Their Forecasts On Edwards Lifesciences Following Q4 Results
Feb 07, 2024 17:30pm

Edwards Lifesciences Corporation (NYSE: EW ) reported in-line earnings for its fourth quarter on Tuesday . Edwards Lifesciences posted adjusted earnings of 64 cents per share, in-line with market expectations of 64 cents per share. The company’s quarterly sales came in at $1.53 billion versus estimates of $1.50 billion, according to data from Benzinga Pro . "In 2023, our team made significant progress advancing transformational therapies for patients while delivering strong financial performance. Full year sales increased 12 percent, including impressive growth across each of our four product groups," said Bernard Zovighian, Edwards’ CEO. "We exited the year with strong … Full story available on Benzinga.com

Earnings call: Edwards Lifesciences reports strong 2023 performance
Feb 07, 2024 12:50pm